Regenerative Medicine and Restorative Tissue Technology Revenue and Competitors

Claim your profile

Miami, FL USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Regenerative Medicine and Restorative Tissue Technology's estimated annual revenue is currently $4.4M per year.(i)
  • Regenerative Medicine and Restorative Tissue Technology's estimated revenue per employee is $112,000

Employee Data

  • Regenerative Medicine and Restorative Tissue Technology has 39 Employees.(i)
  • Regenerative Medicine and Restorative Tissue Technology grew their employee count by -13% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.2M7314%N/AN/A
#2
$230.4M115128%$332.6MN/A
#3
$103.5M752-3%$186.6MN/A
#4
$122.3M69913%N/AN/A
#5
$28.3M188-2%N/AN/A
#6
$4.4M39-13%N/AN/A
#7
$16.7M119-2%$150KN/A
#8
$1.3M15N/AN/AN/A
#9
$1.7M24-45%$54.7MN/A
#10
$1.2M14-18%N/AN/A

Amniox® Medical is the leader in amniotic membrane and umbilical cord regenerative tissue therapies and is supported by more than 25 years of research characterizing and preserving the biology and functionality of human Amniotic Membrane (AM) and Umbilical Cord (UC). AM and UC are restorative tissues that carry unique regenerative properties and Amniox Medical is the sole provider of a matrix comprised of both human AM and UC. Our extensive research allows us to preserve and deliver the most functional allograft, transplanting the benefits of regenerative healing to adult wound environments. As documented in more than 300 peer-reviewed publications, cryopreserved placental tissues have demonstrated the promotion of rapid regenerative healing while suppressing inflammation, scar formation and adhesion. Our patented CRYOTEK™ preservation process maintains the innate biology and structural integrity of the natural tissue; protecting, preserving, and delivering the restorative properties of the AM/UC matrix. Amniox Medical and Bio-Tissue, the global AM leader in ophthalmology, are technology partners with TissueTech, Inc., the developer of the innovative CRYOTEK technology. Bio-Tissue/Amniox Products have been implanted in humans in more than 500,000 cases with an excellent safety record. NEOX® Wound Matrix is indicated for use as a wound covering for dermal ulcers and defects. CLARIX® Regenerative Matrix is indicated for use as a surgical covering, wrap or barrier. NEOX® FLO and CLARIX® FLO are the particulate forms of NEOX® wound matrix and CLARIX® regenerative matrix.

keywords:N/A

N/A

Total Funding

39

Number of Employees

$4.4M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Regenerative Medicine and Restorative Tissue Technology News

2022-04-20 - FDA Grants Regenerative Medicine Advanced Therapy ...

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus' CAR T cell ... Autolus Therapeutics plc (GLOBE NEWSWIRE); Apr...

2022-04-17 - Enzyvant to build regenerative medicine manufacturing plant ...

Enzyvant, which focuses on developing regenerative medicines for rare diseases, has laid out plans to build a new manufacturing facility in...

2022-03-22 - Engineering researchers develop porous nanoparticles for ...

... develop porous nanoparticles for regenerative medicine ... the body's regenerative potential by directing stem cells to form bone tissue...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.8M39-7%N/A
#2
$3.9M39-13%$20M
#3
$6.5M3915%N/A
#4
$6.5M395%N/A
#5
$6.8M3915%N/A